Skip to Content

'
Colin P. Dinney, MD

Present Title & Affiliation

Primary Appointment

Chairman, Department of Urology, Division of Surgery, University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Biology, Division of Basic Science Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1982 University of Manitoba, Winnipeg, Canada, MD, Medicine
1978 University of Manitoba, Winnipeg, Canada, BS, Microbiology

Postgraduate Training

7/1990-6/1992 Fellow, Department of Urology, Surgery, UT M. D. Anderson Cancer Center, Houston, TX
7/1986-6/1989 Research Fellowship, Urology, Dalhousie University, Halifax, Canada
7/1984-6/1986 Faculty of Medicine, Department of Surgery, Surgery, Dalhousie University, Halifax, Canada
7/1983-6/1984 Research Fellow, Department of Surgery, Surgery, Dalhousie University, Halifax, Canada
7/1982-6/1983 Rotating Internship, Medicine, Dalhousie University, Halifax, Canada

Board Certifications

1/1989 Fellowship of Royal College of Physicians FRCP(S)

Experience/Service

Academic Appointments

Professor, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2002-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Matin SF, Feeley T, Kennamer D, Corriere JN, Miles M, Kays C, Green H, Craig CE, Dinney CP. Office Cystoscopy and Transrectal Ultrasound-guided Prostate Biopsies Pose Minimal Risk: Prospective Evaluation of 921 Procedures. Urology. e-Pub 4/9/2009. PMID: 19362332.
2. Kassouf W, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. Urology, 10/8/2008. e-Pub 10/8/2008. PMID: 18848348.
3. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B. Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection. J Natl Cancer Inst 100(19):1401-11, 9/23/2008. e-Pub 9/23/2008. PMID: 18812553.
4. Gu J, Horikawa Y, Chen M, Dinney CP, Wu X. Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 17(9):2445-50, 9/2008. PMID: 18768515.
5. Dinney CP. Bladder cancer. Urol Oncol 26(5):479-80, Sep-Oct, 9/2008. PMID: 18774458.
6. Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, Bar-Eli M, McConkey DJ, Adam L, Dinney CP. Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer? J Urol 180(3):1146-53, 7/16/2008. e-Pub 7/18/2008. PMID: 18639280.
7. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112(11):2467-74, 6/1/2008. PMID: 18361427.
8. Liang D, Lin J, Grossman HB, Ma J, Wei B, Dinney CP, Wu X. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control 19(9):981-92, 5/14/2008. e-Pub 5/14/2008. PMID: 18478342.
9. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. J Urol 180(1):164-7; discussion 167, 5/14/2008. PMID: 18485384.
10. Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou JH, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa JP, Benedict WF, Scherer SE, Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest 88(7):694-721, 5/5/2008. PMID: 18458673.
11. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 68(7):2530-7, 4/1/2008. PMID: 18381463.
12. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236-44, 4/1/2008. PMID: 18381966.
13. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 3/1/2008. PMID: 18316572.
14. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519-25, 3/2008. PMID: 18342201.
15. Zhu Y, Yang H, Chen Q, Lin J, Grossman HB, Dinney CP, Wu X, Gu J. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 7(2):141-8, 2/1/2008. PMID: 17923445.
16. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 14(1):224-9, 1/1/2008. PMID: 18172274.
17. Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol, 1/11/2008. PMID: 18367107.
18. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179/1(1):353-8, 1/2008. PMID: 18006009.
19. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. J Clin Oncol 26/1(1):121-6, 1/2008. PMID: 18165646.
20. Black PC, Dinney CP. Re: Nomograms provide improved accuracy for predicting survival after radical cystectomy. Eur Urol 51(4):1140-1, Jan-Feb, 4/2007. PMID: 17415911.
21. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 1/110/1:62-67, 2007.
22. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 6:277-285, 2007.
23. Black PC, Dinney CP. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Eur Urol 51:1140-1141, 2007.
24. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M. D. Anderson Cancer Center experience. Cancer, 2007.
25. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. Eur Urol 52(3):769-74, 2007. PMID: 17434254.
26. Lin X, Wood CG, Shao L, Huang M, Yang H, Dinney CP, Wu X. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer 110/2:282-288, 2007.
27. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5:3032-41, 12/2006. PMID: 17172406.
28. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66:11644-8, 12/2006. PMID: 17178858.
29. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176:1463-7, 10/2006. PMID: 16952661.
30. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 107:1491-5, 10/2006. PMID: 16894527.
31. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol 176:1642-7, 10/2006. PMID: 16952707.
32. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68:549-53, 9/2006. PMID: 16979735.
33. Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR, Wu X. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet 70:240-5, 9/2006. PMID: 16922727.
34. Lin J, Dinney CP, Grossman HB, Wu X. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev 15:1746-9, 9/2006. PMID: 16985040.
35. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. Cancer 107:705-11, 8/2006. PMID: 16845665.
36. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12:4671-7, 8/2006. PMID: 16899617.
37. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 176:787-92, 8/2006. PMID: 16813948.
38. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176:53-7; discussion 57, 7/2006. PMID: 16753366.
39. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175:2058-62, 6/2006. PMID: 16697803.
40. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78:464-79, 3/2006. PMID: 16465622.
41. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology 67:466-71, 3/2006. PMID: 16527559.
42. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175:881-5, 3/2006. PMID: 16469571.
43. Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS. The use of urine-based biomarkers in bladder cancer. Urology 67:62-4, 3/2006. PMID: 16530080.
44. Dinney CP. Therapy of invasive bladder cancer. Urology 67:56-9; discussion 60-1, 3/2006. PMID: 16530078.
45. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67:518-23, 3/2006. PMID: 16527570.
46. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65(22):10524-35, 11/2005. PMID: 16288045.
47. Gu J, Spitz MR, Zhao H, Lin J, Grossman HB, Dinney CP, Wu X. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis 26(10):1741-7, 10/2005. PMID: 15905204.
48. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-20, 10/2005. PMID: 16242074.
49. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer 104(5):975-84, 9/2005. PMID: 16044400.
50. Gu J, Grossman HB, Dinney CP, Wu X. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics 6(6):575-84, 9/2005. PMID: 16142998.
51. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746-56, 8/2005. PMID: 16110031.
52. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65(11):4902-8, 6/2005. PMID: 15930312.
53. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, Wu X. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 11(4):1408-15, 2/2005. PMID: 15746040.
54. Goebell PJ, Groshen S, Schmitz-Drager BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res 11(2 Pt 1):413-5, 1/2005. PMID: 15701822.
55. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate, 1/2005.
56. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, Czerniak B. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 85:532-549, 2005.
57. Gabril M, Xuan J, Moussa M, Dinney CP, Chin JL, Izawa JI. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model. Urology 64(6):1233-7, 12/2004. PMID: 15596214.
58. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 64(24):8973-9, 12/2004. PMID: 15604261.
59. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 10(3):525-32, 9/2004. PMID: 15336652.
60. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172(2):481-4, 8/2004. PMID: 15247709.
61. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 8/2004. PMID: 15324694.
62. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22(16):3316-22, 8/2004. PMID: 15310775.
63. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 64(13):4601-10, 7/2004. PMID: 15231672.
64. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3(3):279-90, 3/2004. PMID: 15026548.
65. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 171(2 Pt 1):570-4, 2/2004. PMID: 14713761.
66. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 170(6 Pt 1):2221-4, 12/2003. PMID: 14634383.
67. Pagliaro LC, Keyhani A, Liu B, Perrotte P, Wilson D, Dinney CP. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 21(6):456-62, 11/2003. PMID: 14693272.
68. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 21(5):327-33, 9/2003. PMID: 14670538.
69. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9(8):3167-75, 8/2003. PMID: 12912969.
70. Sweeney P, Karashima T, Ishikura H, Wiehle S, Yamashita M, Benedict WF, Cristiano RJ, Dinney CP. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Res 63(14):4017-20, 7/2003. PMID: 12874000.
71. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 9(7):2786-97, 7/2003. PMID: 12855659.
72. Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology 61(6):1151-5, 6/2003. PMID: 12809885.
73. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169(6):2113-7, 6/2003. PMID: 12771730.
74. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 21(12):2247-53, 6/2003. PMID: 12805322.
75. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, Wu X. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 95(7):540-7, 4/2003. PMID: 12671022.
76. Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF, Hsieh JT. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. J Urol Oncol 21:313-314, 2003.
77. Kedar D, Baker CH, Killion JJ, Dinney CP, Fidler IJ. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 8(11):3592-600, 11/2002. PMID: 12429651.
78. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ, Dinney CP, Killion JJ. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 62(20):5720-6, 10/2002. PMID: 12384530.
79. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-24, 8/2002. PMID: 12171905.
80. Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 9(8):687-91, 8/2002. PMID: 12136430.
81. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8(6):1863-70, 6/2002. PMID: 12060629.
82. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8(5):1253-64, 5/2002. PMID: 12006546.
83. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98(5):682-9, 4/2002. PMID: 11920636.
84. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4):1258-70, 4/2002. PMID: 11948141.
85. Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep 8(5):955-64, 9/2001. PMID: 11496299.
86. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 7(9):2840-53, 9/2001. PMID: 11555602.
87. Lance RS, Dinney CP, Swanson D, Babaian RJ, Pisters LL, Palmer LJ, Grossman HB. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep 8(4):723-6, 7/2001. PMID: 11410772.
88. Slaton JW, Benedict WF, Dinney CP. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57(5):852-9, 5/2001. PMID: 11337281.
89. Mendelsohn J, Dinney CP. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol 165(4):1152-7, 4/2001. PMID: 11257658.
90. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158(2):735-43, 2/2001. PMID: 11159211.
91. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 8(1):9-15, 2001. PMID: 11115562.
92. Dinney CP. Inhibition of angiogenesis and metastasis by blockade of epidermal growth factor receptor. Nishinihon J Urol 63:113-118, 2001.
93. Millikan R, Dinney C, Swanson D, et al:. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant m-vac versus cystectomy with both preoperative and postoperative m-vac. J Clin Oncol 19:4005-4013, 2001.
94. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6(12):4874-84, 12/2000. PMID: 11156247.
95. Pisters LL, Westney OL, Scott S, Swanson DA, Wood CG, Von Eschenbach AC, Dinney CP, McGuire EJ. Pubourethral sling simultaneous with radical retropubic prostatectomy for patients at high risk for postprostatectomy incontinence. Prostate Cancer Prostatic Dis 3(S1):S34, 12/2000. PMID: 12497142.
96. Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6(12):4866-73, 12/2000. PMID: 11156246.
97. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 6(11):4422-31, 11/2000. PMID: 11106263.
98. Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, Dinney CP. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology 56(1):155-9, 7/2000. PMID: 10869658.
99. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, Dinney CP. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6(7):2635-43, 7/2000. PMID: 10914704.
100. Pisters LL, English SF, Scott SM, Westney OL, Dinney CP, McGuire EJ. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol 163(6):1771-4, 6/2000. PMID: 10799179.
101. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6(5):2104-19, 5/2000. PMID: 10815938.
102. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60(8):2290-9, 4/2000. PMID: 10786697.
103. Balbay MD, Slaton JW, Trane N, Skibber J, Dinney CP. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer 86(11):2212-6, 12/1999. PMID: 10590359.
104. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5(10):2726-34, 10/1999. PMID: 10537335.
105. Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 162(3 Pt 1):710-4, 9/1999. PMID: 10458349.
106. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 5(4):783-9, 4/1999. PMID: 10213213.
107. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol 161(2):509-14, 2/1999. PMID: 9915437.
108. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5(2):257-65, 2/1999. PMID: 10037173.
109. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, Fidler IJ. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59(4):872-9, 2/1999. PMID: 10029078.
110. Wood M, Perrotte P, Onishi E, et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 6:367-372, 1999.
111. Hughes J, Katz R, Rodriguez-Villanueva J, Kidd L, Dinney C. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 20:285-290, 1999.
112. Dinney CP, Babkowski RC, Antelo M, Perrotte P, Liebert M, Zhang HZ, Palmer J, Veltri RW, Katz RL, Grossman HB. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 160(4):1285-90, 10/1998. PMID: 9751337.
113. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4(4):829-34, 4/1998. PMID: 9563875.
114. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159(4):1163-7, 4/1998. PMID: 9507823.
115. Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 159(4):1168-73, 4/1998. PMID: 9507824.
116. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 159(3):792-5, 3/1998. PMID: 9474150.
117. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159(2):394-8, 2/1998. PMID: 9649246.
118. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58(4):808-14, 2/1998. PMID: 9485039.
119. Gohji K, Nakajima M, Boyd D, Dinney CP, Bucana CD, Kitazana S, Kamidono S, Fidler IJ. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol 151(6):1655-61, 12/1997. PMID: 9403716.
120. Slaton JW, Balbay MD, Levy DA, Pisters LL, Nesbitt JC, Swanson DA, Dinney CP. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology 50(5):673-7, 11/1997. PMID: 9372873.
121. Pollack A, Czerniak B, Zagars GK, Hu SX, Wu CS, Dinney CP, Chyle V, Benedict WF. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 39(3):687-95, 10/1997. PMID: 9336151.
122. Slaton JW, Dinney CP, Veltri RW, Miller CM, Liebert M, O'Dowd GJ, Grossman HB. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol 158(3 Pt 1):806-11, 9/1997. PMID: 9258087.
123. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol 157(6):2120-3, 6/1997. PMID: 9146596.
124. Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump DS, Swanson DA, Pisters LL, Willis KD, Putnam JB, Jr. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg 63(6):1592-600, 6/1997. PMID: 9205155.
125. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 157(3):921-5, 3/1997. PMID: 9072600.
126. Corral DA, Dinney CP. Radical cystectomy: posterior dissection following prior therapy. J Surg Oncol 64(2):165-6, 2/1997. PMID: 9047257.
127. Dinney CP, Parker C, Dong Z, Fan D, Eve BY, Bucana C, Radinsky R. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res 3(2):161-8, 2/1997. PMID: 9815668.
128. Ghayee H, Dinney C, Pathak S. Do lymphocytes contain chromosomal lesions that are also stable markers in cancer cells? Lymphocyte and tumor cell karyotyping in a melanoma patient. Int J Oncol 11:681-684, 1997.
129. Perrotte P, Bielenberg D, Eve B, Dinney C. Organ-specific angiogenesis and metastasis of human bladder carcinoma growing in athymic mice. Mol Urol 1:299- 307, 1997.
130. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 37(1):41-9, 1997. PMID: 9054875.
131. Kleinerman DI, Dinney CP, Zhang WW, Lin SH, Van NT, Hsieh JT. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res 56(15):3431-5, 8/1996. PMID: 8758907.
132. Hall MC, Swanson DA, Dinney CP. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology 47(6):826-30, 6/1996. PMID: 8677571.
133. de la Roza GL, Hopkovitz A, Caraway NP, Kidd L, Dinney CP, Johnston D, Katz RL. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol 9(5):571-8, 5/1996. PMID: 8733774.
134. Wu CS, Pollack A, Czerniak B, Chyle V, Zagars GK, Dinney CP, Hu SX, Benedict WF. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 47(3):305-10, 3/1996. PMID: 8633392.
135. Kenworthy P, Tanguay S, Dinney CP. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 155(2):501-3, 2/1996. PMID: 8558645.
136. Ippoliti C, Przepiorka D, Mehra R, et al. Intervesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology 46:811-815, 1996.
137. Logothetis C, Swanson D, Amato R, et al. Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective, comparative trial of pre- and post-operative chemotherapy for invasive bladder carcinoma. J Urol 155:1241-1245, 1996.
138. Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 155(1):26-9, 1996. PMID: 7490850.
139. Balat O, Kudelka A, Ro J, et al. Two synchronous primary tumors of the ovary and kidney: a case report. Eur J Gynaec Oncol 17:257-259, 1996.
140. Pettaway CA, Pisters LL, Dinney CP, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol 154(6):1999-2003, 12/1995. PMID: 7500444.
141. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154(6):2059-63; discussion 2063-4, 12/1995. PMID: 7500458.
142. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, Xie B, Fan D, Bucana CD, Fidler IJ, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154(4):1532-8, 10/1995. PMID: 7658585.
143. Dinney CP, Tanguay S, Bucana CD, Eve BY, Fidler IJ. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J Interferon Cytokine Res 15(6):585-92, 6/1995. PMID: 7553228.
144. Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 32(2):331-40, 5/1995. PMID: 7751174.
145. Fornage BD, Dinney CP, Troncoso P. Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. J Clin Ultrasound 23(4):263-5, 5/1995. PMID: 7797666.
146. Dinney CP, Ramirez EI, Swanson DA, Ro JY, Babaian RJ, von Eschenbach AC. Management of transitional cell carcinoma involving von Brunn's nests. J Urol 153(3 Pt 2):944-9, 3/1995. PMID: 7853580.
147. Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer 74(10):2819-27, 11/1994. PMID: 7954243.
148. Amin MB, Ro JY, Lee KM, Ordonez NG, Dinney CP, Gulley ML, Ayala AG. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol 18(5):466-73, 5/1994. PMID: 8172321.
149. Dinney CP, Johnson DE, Swanson DA, Babaian RJ, von Eschenbach AC. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology 43(4):506-14, 4/1994. PMID: 8154072.
150. Babaian RJ, Dinney CP, Ramirez EI, Evans RB. Diagnostic testing for prostate cancer detection: less is best. Urology 41(5):421-5, 5/1993. PMID: 7683834.
151. Dinney CP, Ro JY, Babaian RJ, Johnson DE. Lymphoepithelioma of the bladder: a clinicopathological study of 3 cases. J Urol 149(4):840-1, 4/1993. PMID: 8455255.
152. Gohji K, Nakajima M, Dinney C, et al. The importance of orthotopic implantation to the isolation and biological characterization of a metastatic human clear cell renal carcinoma in nude mice. Int J Oncol 2:23-32, 1993.
153. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 84(12):951-7, 6/1992. PMID: 1378502.
154. Dinney CP, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Cancer Res 52(5):1155-61, 3/1992. PMID: 1531322.
155. Dinney CP, Awad SA, Gajewski JB, Belitsky P, Lannon SG, Mack FG, Millard OH. Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology 39(2):122-9, 2/1992. PMID: 1736503.
156. Utsugi T, Dinney CP, Killion JJ, Brown D, Fidler IJ. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Lymphokine Cytokine Res 10(6):487-93, 12/1991. PMID: 1804312.
157. Dinney CP, Bucana CD, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Cancer Res 51(14):3741-7, 7/1991. PMID: 1905975.
158. Utsugi T, Dinney CP, Killion JJ, Fidler IJ. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol Immunother 33(6):375-81, 1991. PMID: 1878891.
159. Dinney CP, Norman RW. Contralateral pleural effusion secondary to nonmetastatic renal cell carcinoma. J Urol 143(5):1002-3, 5/1990. PMID: 2329586.

Invited Articles
1. Lamm DL, Dinney, C. Advances in Bladder Cancer Treatment of High-Risk Non-Muscle-Invasive TCC: An Ongoing Debate. Renal & Urology News Part 4, 2/2008.
2. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 9(1):55-61, 1/2008. PMID: 18366975.
3. Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol 24:531-42, 11/2006. PMID: 17115230.
4. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol 3:472-3, 9/2006. PMID: 16964186.
5. Black PC, Brown GA, Dinney CP. Should cystectomy only be performed at high-volume hospitals by high-volume surgeons? Curr Opin Urol 16:344-9, 9/2006. PMID: 16905980.
6. Adam L, Kassouf W, Dinney CP. Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am 32(2):239-46, vii, 5/2005. PMID: 15862621.
7. Highshaw RA, McConkey DJ, Dinney CP. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Curr Opin Urol 14(5):295-300, 9/2004. PMID: 15300150.
8. Grossman HB, Dinney CP. If cystectomy is insufficient, what is an urologist to do? Urol Oncol 21(6):475-8, 11/2003. PMID: 14693276.
9. Canfield SE, Dinney CP, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am 30(4):791-802, 11/2003. PMID: 14680315.
10. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46 Suppl:S85-104, 6/2003. PMID: 12850530.
11. Dinney CP, Bermejo CE. Treating bladder cancer and getting back in the game. Coping, 4/2003.
12. Rosser CJ, Benedict WF, Dinney CP. Gene therapy for superficial bladder cancer. Expert Rev Anticancer Ther 1(4):531-9, 12/2001. PMID: 12113085.
13. Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancers: a review. Cmaj 164(5):662-70, 3/2001. PMID: 11258215.
14. Hsieh JT, Dinney CP, Chung LW. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am 27(1):103-13, ix, 2/2000. PMID: 10696249.
15. Grossman HB, Dinney CP. Markers of bladder cancer: state of the art. Urol Oncol 5:3-10, 2000.
16. Hall CM, Dinney CP. Radical cystectomy for stage T3b bladder cancer. Semin Urol Oncol 14(2):73-80, 5/1996. PMID: 8734734.
17. Millikan R, Dinney CP. The role of chemotherapy in the management of the patient with T3b bladder cancer. Semin Urol Oncol 14(2):81-5, 5/1996. PMID: 8734735.
18. Dinney CP. Optimal treatment for androgen-dependent prostate tumors. Cancer Bull 45:418-423, 1993.

Book Chapters
1. Steinberg JR, Dinney CPN, Grossman HB. Screening, early detection, and prevention of bladder cancer. In: Comprehensive Textbook of Genitourinary Oncology, Third Edition. Ed(s) NJ Vogelzang, PT Scardino, WU Shipley, FMJ Debruyne, WM Linehan. Lippincott, Williams & Wilkins: Philadelphia, 403-410, 2006.
2. Kassouf W, Bochner BH, Dinney CP. Targeted therapy for bladder cancer. In: Textbook of Bladder Cancer. Ed(s) SP Lerner, MP Schoenberg, CN Sternberg. Taylor & Francis: United Kingdom, 695-710, 2006.
3. Sweeney P Dinney CPNDroller MJ. Molecular pathogenesis of proliferative and progressive (invasive) urothelial cancer development. In: American Cancer Society Atlas of clinical Oncology Urothelial Tumors. BC Decker, Inc., 44-57, 2004.
4. Huang S, Dinney CPN. Genitourinary cancer. In: M. D. Anderson Surgical Oncology Handbook. Lippincott Williams & Wilkins, 425-444, 2003.
5. Canfield SE, Dinney CPN, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. In: The Urologic Clinics of North America. Follow-up Strategies and Management of Recurrence in Urologic Oncology. W. B. Saunders Company, 791-802, 2003.
6. Pettaway C, Dinney C. Urologic and male genital cancer. Section F: Penile and urethral cancer. In: Clinical Oncology. American Cancer Society, 2000.
7. Delworth M, Dinney C. Genitourinary cancer. In: M. D. Anderson Handbook of Surgical Oncology. Little, Brown and Company, 308-325, 1999.
8. Dinney C, Pisters L, von Eschenbach AC. Cryoablation for prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams & Wilkins, 828-837, 1998.
9. Dinney CP, Fidler I. Biology of metastasis: studies in renal cancer. In: Principles and Practice of Genitourinary Oncology. Lippincott-Raven Publishers, 1996.
10. Fidler I, Dinney C, Killion J. Therapy of murine spontaneous renal cancer metastases by coadministration of Liposomes containing macrophage activators and cytokines. In: Hemopoietic Growth Factors and Mononuclear Phagocytes, 148-156, 1993.
11. Dinney CP, Stephenson R. Flow cytometry in urologic oncology. In: Pathophysiologic Principles of Urology. Blackwell Scientific Publications, Inc., 431-454, 1991.

Grant & Contract Support

Title: UT MD Anderson SPORE in Genitourinary Cancers
Funding Source: NIH
Role: Principal Investigator
Duration: 9/1/2006 - 8/31/2011

Last updated: 9/9/2009